Latest news with #PrEP
USA Today
a day ago
- Business
- USA Today
Corporations won't save LGBTQ+ people. Take their money for Pride anyway.
Corporations won't save LGBTQ+ people. Take their money for Pride anyway. | Opinion Every large company, regardless of its position on DEI, operates within systems that perpetuate harm in one way or another. This is not a time to stand on principle. Take the money. Show Caption Hide Caption San Francisco Pride faces shortfall as corporate sponsors pull out Several major companies have opted out of donating to San Francisco Pride this year, such as Anheuser-Busch, Diageo, Nissan, and Comcast. Corporations are not our friends. Despite their diverse casting in advertisements, the rainbow trinkets they proudly sell for $2, press releases on innovative DEI initiatives or how "brave" their hot takes on social issues are – corporations will not save us. They exist to sell us things. They exist to advertise their brand. They exist to maximize their profits. And our job as queer leaders is not to be the morality police of who can or cannot sponsor pride or donate toward LGBTQ+ events and causes; our job is to grab that money and use it to support a community on the brink of being pummeled. This is not a normal year. Federal funding for nonprofits supporting LGBTQ+, immigrant, people of color and other intersecting communities are under attack, as are our tax-exempt statuses. Economists are predicting massive layoffs. Libraries, museums, cultural spaces and health programs (which employ and serve countless LGBTQ+ individuals) are being defunded. Trump administration has waged war on trans people Our federal government has waged an egregious war on our trans family, and the Supreme Court recently heard a case that could dismantle all preventative care coverage, including access to PrEP (pre-exposure prophylaxis medicine that can help prevent the spread of HIV). Here is the hard truth we have to reckon with in 2025: Every dollar counts more than ever if we want to keep LGBTQ+ people informed, healthy and alive. There's a commendable vision within the LGBTQ+ community to return to a time when we relied on mutual aid instead of corporate dollars. But like everything, it has a cost. In 2025, that cost is asking a community of people who are losing access to meds, about to lose their jobs and constantly under political attack to give even more. Your Turn: Do you celebrate pride? Are you worried about Trump's impacts on it? Tell us. The quiet truth is it would financially decimate our community if we were expected to take the already small amount of resources that we have and use them to replace hundreds of millions dollars in lost sponsorships, research and health care. Most people can't afford to donate to every fundraiser providing continuous access to gender-affirming care, send money to replace funding for the local trans services that lost their federal grant, give to all the GoFundMe's for everyone getting laid off this year, donate to support some research project still happening and still manage to support the normal fundraising needs our community has on whatever is left in their pockets between paydays. We become stronger by bringing more resources into the fold, not recycling what we have over and over. Pride events must take every dollar from any corporation The truth is, no corporation is ever clean. There is no ethical consumption under capitalism. Every large company ‒ regardless of its position on diversity, equity and inclusion ‒ operates within systems that perpetuate harm in one way or another. How is DEI the deal breaker for who can sponsor pride, but we'll turn a blind eye to a health insurance conglomerate with questionable tactics, companies that destroy the environment or banks supporting genocide? In any other year, I would be asking you to throw them all out. Today I'm asking you to take all of their money. Opinion: With Trump's ban on trans troops in effect, US tests lawful discrimination This is my ask, if you're running a pride festival or charity event, determine the minimum amount you need to make your event a reality, and build a regranting program to get excess funds to community resources under attack this year. This includes your local HIV clinic or programs providing gender-affirming care. If your nonprofit receives corporate gifts or grants, continue to accept the gifts that keep your doors open. But here's the key: Promise corporations the bare minimum in return for their sponsorships. Brainstorm with your team to reexamine what you offer your partners. Are there promotional aspects that could be tweaked, or partnerships toned down, so you are still offering something of value to the partner but it's more authentic to the organization? A little wiggle room leads to big gains. It's time to fight for our survival, not stand on principle If these companies are willing to give us the bare minimum, in the form of a tax-deductible donation, we can afford to give them the bare minimum in return to keep our community stable. Use them to build our own mutual aid bank. Take that dollar. Because in six months or a year, we probably won't have it. Our nonprofits might be starting to shut down. Services will likely be more strained or cut off completely. This is not a time to stand on principle about which funding sources are 'pure.' It's a time to rally, strategize and fight for survival. Every dollar we take and redirect to our community is a necessary, and perhaps fleeting, lifeline – using the advertising capital of a festival or a one-time event, to protect the health, safety and knowledge of our community. To nonprofit leaders and community organizers reading this: Take the money. All of it. Use it to get more medicine, more stability and more resources into your communities. Raise it now so we have it tomorrow. Ask for more, too. We're not just fighting for the present; we're fighting to preserve a future for LGBTQ+ communities everywhere. And that fight requires every dollar we can muster. Missy Spears is the executive director of Queer Kentucky, the GLAAD-nominated media nonprofit that uses the power of storytelling to impact LGBTQ+ culture and health. In addition to her work with Queer Kentucky, Spears serves as the Board of Directors co-president for the Kentucky Civic Engagement Table, the cofounder of the COVunity Free Fridge Program, and sits on Community Advisory Boards for the Cincinnati Art Museum, media outlet WCPO, and University of Kentucky's Center for Clinical and Translational Science. This column originally appeared in the Louisville Courier Journal.
Yahoo
3 days ago
- Business
- Yahoo
Gilead Sciences Stock Gains 21% YTD: Buy, Sell or Hold?
Biotech giant Gilead Sciences, Inc. GILD has put up a strong performance amid a volatile market. Shares of this biotech giant have gained 21.1% year to date against the industry's decline of 4.7%. The stock has outperformed the sector and the S&P 500 Index in this timeframe. Image Source: Zacks Investment Research Gilead Sciences is a dominant player in the HIV market with market-leading treatments. Its diverse portfolio also includes drugs for liver, hematology/oncology and inflammation/respiratory diseases. Approval of new drugs, encouraging pipeline progress and positive data readouts have boosted investors' sentiment in the past six months. However, the oncology business is under pressure. Let's delve into GILD's strengths and weaknesses to analyze how to play the stock at present. Gilead's flagship drug, Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg, BIC/FTC/TAF), for HIV-1 infection has become the number-one prescribed regimen for both treatment-naïve and switch patients. Biktarvy accounts for over 51% share of the treatment market in the United States and should maintain momentum for GILD in the upcoming quarters. Descovy (FTC 200 mg/TAF 25 mg) for pre-exposure prophylaxis (PrEP) is also witnessing good uptake. It maintains over 40% market share in the PrEP market in the United States. Gilead's efforts to innovate its HIV portfolio are impressive. Late-stage studies, PURPOSE 1 and PURPOSE 2, validated lenacapavir's potential to prevent HIV. The FDA accepted new drug application submissions for twice-yearly lenacapavir for HIV prevention under priority review, with a target action date of June 19, 2025. The European Medicines Agency validated the Marketing Authorization Application and EU-Medicines for All application for twice-yearly lenacapavir for HIV prevention. The successful development and potential approval of lenacapavir for the prevention of the disease should solidify Gilead's HIV franchise. Per GILD, lenacapavir, with its twice-yearly dosing, could set a new bar for HIV prevention and allow PrEP to reach a larger number of people who could benefit from a prevention regimen. The FDA approval of seladelpar for the treatment of primary biliary cholangitis (PBC) has strengthened GILD's liver disease portfolio and validated its CymaBay acquisition. The drug's initial uptake is encouraging. The candidate was approved under the brand name Livdelzi. Gilead also recently received conditional marketing authorization from the European Commission for seladelpar for the treatment of PBC. Gilead's oncology portfolio, comprising the Cell Therapy franchise and breast cancer drug Trodelvy, has diversified its overall business. However, the Cell Therapy franchise, comprising Yescarta and Tecartus, is currently under pressure due to competitive headwinds in the United States and Europe that are expected to continue in 2025. Breast cancer drug Trodelvy's sales were lower than expected in the first quarter due to inventory dynamics. Gilead announced positive top-line results from the phase III ASCENT-03 study on Trodelvy, which showed highly statistically significant and clinically meaningful improvement in progression-free survival in patients with first-line metastatic triple-negative breast cancer (mTNBC) who are not candidates for checkpoint inhibitors. The potential launch of anito-cel in multiple myeloma and Trodelvy in first-line mTNBC in 2026 will strengthen the company's oncology business. From a valuation standpoint, GILD is expensive. According to the price/earnings ratio, GILD's shares currently trade at 13.70x forward earnings, lower than the large-cap pharma industry's average of 14.62X but higher than its mean of Source: Zacks Investment Research Earnings estimates for GILD have moved north in the past 60 days. The bottom-line estimate for 2025 has increased to $7.91 from $7.87, while that for 2026 has improved to $8.39 from $8.31. Image Source: Zacks Investment Research Large biotech companies are generally considered safe havens for investors interested in this sector as they are well equipped to weather the uncertain macroenvironment. GILD is one of the dominant players in the HIV market. Gilead's efforts to constantly innovate its HIV portfolio should enable it to maintain growth amid competition from GSK plc GSK. GILD has also collaborated with Merck MRK to evaluate the investigational combination of islatravir and lenacapavir for the treatment of HIV. The potential launch of lenacapavir for PrEP in 2025 will be a significant boost for the company. Gilead's strategic deals and acquisitions to diversify its business are encouraging. However, Biktarvy sales are expected to be under pressure due to Medicare Part D redesign, which, in turn, should impact overall HIV growth. Hence, we advise prospective investors to wait and watch how well Biktarvy and the oncology business combat the existing headwinds before making a positive investment decision. In addition, we believe investors should also wait for better entry levels. For investors already owning the stock, it's important to note that Gilead has been consistently increasing and paying out dividends. The company declared a quarterly dividend of $0.79 per share of common stock for the second quarter of 2025. Its strong cash position (as of March 31, 2025, GILD had $7.9 billion of cash, cash equivalents and marketable debt securities) indicates that the current yield of 2.91% is sustainable. Gilead presently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK) : Free Stock Analysis Report Merck & Co., Inc. (MRK) : Free Stock Analysis Report Gilead Sciences, Inc. (GILD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
UPI
3 days ago
- Health
- UPI
Eight times more young adults now take HIV prevention meds
More young Americans are taking antiretroviral meds to protect them from HIV infection than a decade ago. File Photo by John Angelillo/UPI | License Photo Eight times more young Americans are taking antiretroviral meds to protect them from HIV infection than a decade ago, a new study says. About 208 of every 100,000 U.S. young adults were using pre-exposure prophylaxis, or PrEP, to prevent becoming infected with HIV in 2023, researchers reported recently in the Journal of General Internal Medicine. That's up from 26 of 100,000 who filled a prescription for PrEP pills in 2016, researchers found in their analysis of data for 18- to 25-year-olds. "This is a patient population we often neglect in health care, because we don't think about them belonging to pediatric care or adult care, and their stage of cognitive development means they underestimate their STI [sexually transmitted infection] risk in general - yet they're one of the highest risk groups for a new diagnosis of HIV," said lead researcher Dr. Nina Hill, a general internist and pediatrician at the University of Michigan Medical School. "We're encouraged to see more prescribing over time, but the question remains: are we getting it to the highest-risk patients?" Hill added in a news release. For the study, researchers analyzed records on more than 1.4 million PrEP prescriptions dispensed to nearly 240,000 young adults between 2016 and 2023. The first PrEP medication, Truvada, was introduced in 2012 and became available as a generic drug in 2020, researchers said in background notes. A second oral option, Descovy, became available in 2019. The drugs reduce the chances of acquiring HIV through sex by 99%, when taken consistently as prescribed, researchers said. Nearly 9 of 10 (87%) of the prescriptions went to men, but Hill noted that some women also are at risk for HIV and could be eligible for PrEP. Unfortunately, results also showed that the length of time a person remained on PrEP declined by more than two weeks. This might indicate inconsistent use of PrEP, or show that young adults have trouble keeping up with the appointments and tests needed to continue the medication, researchers said. Nurse practitioners accounted for 39% of the prescriptions, while family doctors handed out 22% of the scrips, results show. Internists and physician assistants accounted for 14% and 11%, respectively. PrEP has been recommended since 2019 by the U.S. Preventive Services Task Force for teens and adults with an increased risk of acquiring HIV, researchers said. Under the Affordable Care Act, most insurance programs are required to make PrEP and HIV screening available to patients at no cost. However, the ACA's preventive care provisions are now under review at the U.S. Supreme Court, and a ruling is expected soon. More information The U.S. Department of Health & Human Services has more on pre-exposure prophylaxis. Copyright © 2025 HealthDay. All rights reserved.
Straits Times
3 days ago
- Health
- Straits Times
Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty
Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over the Trump Administration's pullback in aid spending. Some AIDS experts, including activists and doctors, say the Gilead drug, lenacapavir, could help end the 44-year-old epidemic that infects 1.3 million people a year and is estimated by the World Health Organization to have killed more than 42 million. An FDA approval decision is expected by June 19 for lenacapavir, which proved to be nearly 100% effective at preventing HIV in large trials. If the Food and Drug Administration green lights the drug, and its view is seconded by the WHO, the shots could start to roll out early in 2026 to at least 2 million people in 18 low-income countries based on Gilead's agreement with the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund, a worldwide partnership targeting HIV, tuberculosis and malaria. Gilead agreed to provide lenacapavir at cost for two-to-three years while six generic drugmakers, which were granted licenses to make the medicine for low-income countries, ramp up production. Experts said a successful launch of a long-acting HIV prevention drug could help stall the epidemic. Until recently, the only pre-exposure prophylaxis (PrEP) options for people at high risk of infection were daily pills, requiring careful adherence to be effective. "You can foresee a day where there are no new HIV diagnoses. It doesn't happen if we only do this in the U.S.," Gilead Chief Commercial Officer Johanna Mercier said. "We need to make sure we have a global approach to this launch." PEPFAR being part of the effort is Gilead's intent and goal, Mercier said. "Unfortunately, if they're not part of that mix, our goal is still to meet that objective of 2 million people getting access." Wall Street has a close eye on lenacapavir, one of the highest-profile drugs to undergo FDA review since President Donald Trump named Robert F. Kennedy Jr. as health secretary and promised to upend the status quo. Most of the drug's profits are expected in the U.S., with annual sales reaching $1 billion by next year, according to analysts' estimates compiled by LSEG. 'INCREDIBLE DISMAY' Whether all of the agreed funding for low-income countries - most of which are in Africa - will come through is unclear. Countries that rely on aid are already reeling from funding cuts by the Trump Administration, including to PEPFAR, and AIDS researchers are bracing for the worst. The United Nations program on HIV/AIDS earlier this month said many HIV prevention programs supported by PEPFAR were stalled, although services for pregnant and breastfeeding women were technically exempt from the cuts. Peter Sands, executive director of the Global Fund, told Reuters the group intends to fund as much of the lenacapavir rollout as possible, but it will need to start slowly. "It's not just the uncertainty over PEPFAR's funding that's an issue, but the uncertainty over our funding," Sands said, adding that the group's first priority is treating people already infected with the deadly virus. Much will depend on the success of the Global Fund's effort to raise $18 billion to fund its work from 2027-2029. The U.S. is its largest donor, committing $6 billion in the previous funding round. It is unclear what the U.S. may provide this round, or whether other big governments will step up. UNAIDS estimates that the permanent discontinuation of HIV prevention and treatment programs supported by PEPFAR would lead to an additional 6.6 million new HIV infections between 2025 and 2029. The U.S. State Department, which oversees PEPFAR, did not respond to a request for comment. Gilead declined to comment on its manufacturing cost for lenacapavir, whose U.S. price is likely to be on par with current preventive medications at around $25,000 per year. ViiV Healthcare's Apretude, an injection given every two months, costs about 124.20 pounds ($168) in low- and middle-income countries. Mitchell Warren, executive director of the AIDS nonprofit AVAC, estimates the eventual annual cost at $100-$120. The lower the price, the more people who could receive it, he said. Warren said PEPFAR could still participate, and others may come forward. The Gates Foundation and the Children's Investment Fund Foundation are "actively involved in all of these conversations," he said, as is the Elton John AIDS Foundation. Linda-Gail Bekker of the University of Cape Town, who led lenacapavir clinical trials in South Africa and Uganda, said she was elated when she first saw the findings. "The huge feeling I have now is one of incredible dismay," said Bekker of uncertainty over the Trump administration's commitment to PEPFAR and HIV prevention in poor nations. "It felt like the stars were aligning, and one of the stars has fallen out of the sky." REUTERS Join ST's Telegram channel and get the latest breaking news delivered to you.
The Star
3 days ago
- Health
- The Star
Gilead commits to HIV prevention rollout for low-income countries despite funding uncertainty
(Reuters) -Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over the Trump Administration's pullback in aid spending. Some AIDS experts, including activists and doctors, say the Gilead drug, lenacapavir, could help end the 44-year-old epidemic that infects 1.3 million people a year and is estimated by the World Health Organization to have killed more than 42 million. An FDA approval decision is expected by June 19 for lenacapavir, which proved to be nearly 100% effective at preventing HIV in large trials. If the Food and Drug Administration green lights the drug, and its view is seconded by the WHO, the shots could start to roll out early in 2026 to at least 2 million people in 18 low-income countries based on Gilead's agreement with the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund, a worldwide partnership targeting HIV, tuberculosis and malaria. Gilead agreed to provide lenacapavir at cost for two-to-three years while six generic drugmakers, which were granted licenses to make the medicine for low-income countries, ramp up production. Experts said a successful launch of a long-acting HIV prevention drug could help stall the epidemic. Until recently, the only pre-exposure prophylaxis (PrEP) options for people at high risk of infection were daily pills, requiring careful adherence to be effective. "You can foresee a day where there are no new HIV diagnoses. It doesn't happen if we only do this in the U.S.," Gilead Chief Commercial Officer Johanna Mercier said. "We need to make sure we have a global approach to this launch." PEPFAR being part of the effort is Gilead's intent and goal, Mercier said. "Unfortunately, if they're not part of that mix, our goal is still to meet that objective of 2 million people getting access." Wall Street has a close eye on lenacapavir, one of the highest-profile drugs to undergo FDA review since President Donald Trump named Robert F. Kennedy Jr. as health secretary and promised to upend the status quo. Most of the drug's profits are expected in the U.S., with annual sales reaching $1 billion by next year, according to analysts' estimates compiled by LSEG. 'INCREDIBLE DISMAY' Whether all of the agreed funding for low-income countries - most of which are in Africa - will come through is unclear. Countries that rely on aid are already reeling from funding cuts by the Trump Administration, including to PEPFAR, and AIDS researchers are bracing for the worst. The United Nations program on HIV/AIDS earlier this month said many HIV prevention programs supported by PEPFAR were stalled, although services for pregnant and breastfeeding women were technically exempt from the cuts. Peter Sands, executive director of the Global Fund, told Reuters the group intends to fund as much of the lenacapavir rollout as possible, but it will need to start slowly. "It's not just the uncertainty over PEPFAR's funding that's an issue, but the uncertainty over our funding," Sands said, adding that the group's first priority is treating people already infected with the deadly virus. Much will depend on the success of the Global Fund's effort to raise $18 billion to fund its work from 2027-2029. The U.S. is its largest donor, committing $6 billion in the previous funding round. It is unclear what the U.S. may provide this round, or whether other big governments will step up. UNAIDS estimates that the permanent discontinuation of HIV prevention and treatment programs supported by PEPFAR would lead to an additional 6.6 million new HIV infections between 2025 and 2029. The U.S. State Department, which oversees PEPFAR, did not respond to a request for comment. Gilead declined to comment on its manufacturing cost for lenacapavir, whose U.S. price is likely to be on par with current preventive medications at around $25,000 per year. ViiV Healthcare's Apretude, an injection given every two months, costs about 124.20 pounds ($168) in low- and middle-income countries. Mitchell Warren, executive director of the AIDS nonprofit AVAC, estimates the eventual annual cost at $100-$120. The lower the price, the more people who could receive it, he said. Warren said PEPFAR could still participate, and others may come forward. The Gates Foundation and the Children's Investment Fund Foundation are "actively involved in all of these conversations," he said, as is the Elton John AIDS Foundation. Linda-Gail Bekker of the University of Cape Town, who led lenacapavir clinical trials in South Africa and Uganda, said she was elated when she first saw the findings. "The huge feeling I have now is one of incredible dismay," said Bekker of uncertainty over the Trump administration's commitment to PEPFAR and HIV prevention in poor nations. "It felt like the stars were aligning, and one of the stars has fallen out of the sky." (Reporting by Julie Steenhuysen in Chicago and Deena Beasley in Los Angeles; additional reporting by Jennifer Rigby in London; editing by Caroline Humer and Bill Berkrot)
